AKT1 and lung carcinoma: Zhu et al. revealed that SLCO2A1 is a promising therapeutic target for lung cancer in that it mediates the invasion and apoptosis of lung cancer cells through the PI3K/AKT/mTOR pathway (Zhu et al., 2015).